drugset / Trial / NCT04161755
Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
Phase 1
Active not recruiting
29 enrolled
Memorial Sloan Kettering Cancer Center
Genentech, Inc. · collabMassachusetts Institute of Technology · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety or treating pancreatic cancer with surgery to remove cancerour tissue, followed by atezolizumab, followed by a personalized cancer vaccine (PCV), and then with chemotherapy.
Timeline
- Start
- 2019-12-13
- Primary completion
- 2026-11-11
- Completion
- 2026-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | — |
| Subject | Autogene cevumeran | Messenger RNA (mRNA) | — | — |